Inquiry Basket
Antigen design is one of the most critical—and often one of the most challenging—steps in vaccine development. A well-designed antigen must not only mimic key structural features of a pathogen or tumor-associated protein, but also be stably expressed, properly folded, and immunogenic in the desired host system. Despite advances in bioinformatics and structural biology, many vaccine programs still encounter significant bottlenecks when translating in silico antigen designs into viable experimental constructs.
Traditional cloning and expression workflows frequently introduce delays and inefficiencies: codon usage mismatches, cryptic regulatory signals, unstable sequences, or poorly expressed protein domains can all hinder progress. As timelines tighten and the complexity of vaccine targets increases, researchers need faster, more reliable methods for engineering and producing high-performance antigens. Custom synthetic DNA offers a powerful solution to these challenges. By enabling rapid and precise manipulation of genetic sequences—including codon usage, regulatory elements, and epitope configurations—synthetic DNA accelerates construct optimization while reducing experimental risk. In this article, we examine common pitfalls in antigen design, explore how synthetic DNA technologies overcome these limitations, and provide a case study illustrating their impact on protein yield and function.
The design of antigens is a foundational step in vaccine development, directly influencing the safety, efficacy, and manufacturability of the final product. While advances in synthetic biology and structural vaccinology have improved our ability to rationally design antigens, several recurring challenges persist. These pitfalls can undermine the immunogenic performance of a candidate vaccine or stall its progress altogether. Among the most common issues are low expression levels in host cells, immunogenic complications arising from the use of wild-type sequences, and the inherent difficulty in producing specific protein domains. Understanding and addressing these problems is essential for optimizing antigen candidates and accelerating the transition from discovery to clinical development.
A major barrier to efficient vaccine production is the suboptimal expression of recombinant antigens in host systems such as E. coli, yeast, insect cells, or mammalian cells. Poor expression levels not only reduce yield but also hinder the ability to conduct functional assays, purification, and stability testing—critical steps for down-stream development. Low expression is often rooted in codon usage bias, mRNA secondary structures that impede ribosome access, or the presence of cryptic splice sites and premature polyadenylation signals. Additionally, proteins that require extensive post-translational modifications or complex folding pathways may misfold or be degraded by host quality-control mechanisms. For example, membrane-bound or multi-domain antigens with disulfide bonds often require expression in eukaryotic systems, but even these may fail without optimization.
Another pitfall lies in the direct use of wild-type pathogen sequences for antigen design. While these native sequences may seem like logical candidates due to their biological relevance, they often pose challenges from an immunogenicity standpoint. Wild-type proteins may be structurally unstable, contain glycosylation motifs that shield key epitopes, or present epitopes that elicit suboptimal immune responses. In some cases, they may even trigger immune tolerance rather than activation. For instance, in the development of subunit vaccines for viruses like HIV, RSV, or influenza, native proteins frequently adopt conformations that hide neutralizing epitopes. Moreover, certain wild-type sequences may include dominant but non-protective epitopes that distract the immune system from more relevant targets. In bacterial antigens, conserved regions may be poorly immunogenic or cross-reactive with host proteins, increasing the risk of autoimmunity.
Certain protein domains present intrinsic production challenges, even in optimized expression systems. These domains may be highly hydrophobic, prone to aggregation, sensitive to proteolysis, or toxic to the host cell. Examples include transmembrane regions, fusion peptides, and certain flexible loops that are essential for function but notoriously difficult to express and purify. One particularly vexing issue is the expression of conformational epitopes that depend on precise domain-domain interactions. If one domain misfolds or fails to interact correctly with neighboring regions, the antigen may lose its functional or immunogenic properties. This is especially problematic in multimeric viral proteins or large bacterial toxins, where subunit interactions are critical for native structure.
The advent of synthetic DNA has transformed molecular biology, particularly in vaccine research, gene therapy, and synthetic biology. Compared to traditional cloning methods that rely on labor-intensive PCR, restriction enzymes, and ligation, synthetic DNA offers a streamlined, highly customizable, and scalable alternative. It enables rapid iteration of constructs, precise sequence control, and the ability to overcome biological limitations that often hamper conventional approaches. This technological advancement is especially advantageous in antigen design, where the ability to fine-tune sequences can determine the success of a therapeutic candidate. Below, we explore three critical advantages that make synthetic DNA superior: codon harmonization across species, easy variant generation for epitope mapping, and the elimination of toxic or unstable sequence elements.
One of the major challenges in heterologous protein expression is the discrepancy in codon usage between the source organism and the host expression system. Traditional cloning methods often import wild-type sequences directly into expression hosts like E. coli, yeast, or mammalian cells, without accounting for species-specific codon preferences. This mismatch can result in poor translation efficiency, truncated proteins, or misfolded products due to ribosome stalling and imbalanced tRNA availability. Synthetic DNA allows for precise codon harmonization—adapting the codon usage of the gene to match that of the host organism while preserving translation dynamics and protein folding pathways. Unlike simple codon optimization, which merely substitutes rare codons with frequent ones, harmonization also considers the rate of translation elongation to support proper co-translational folding. This is especially important for complex antigens that depend on specific domain structures or disulfide bond formation for functional integrity. Moreover, synthetic DNA can incorporate additional regulatory elements such as Kozak sequences, ribosome binding sites, or polyadenylation signals tailored to the host, further enhancing expression. By preemptively designing for compatibility, synthetic constructs often produce higher yields, better solubility, and more consistent batch-to-batch performance, streamlining both research and manufacturing processes.
Understanding which parts of an antigen elicit protective immune responses is critical for vaccine development. Epitope mapping involves systematic mutation or deletion of antigen regions to assess their impact on antibody binding, T cell activation, or neutralizing activity. Traditionally, this process requires cloning and mutating one construct at a time—a tedious and time-consuming workflow that limits the number of variants researchers can feasibly study.
Synthetic DNA accelerates this process by enabling high-throughput variant generation. Dozens—or even hundreds—of constructs can be synthesized in parallel, each encoding targeted mutations, deletions, or insertions. This allows for fine-resolution scanning of antigenic surfaces, glycosylation sites, or conformational epitopes, facilitating the identification of immune-dominant regions or escape-prone mutations. Such flexibility is invaluable in pandemic preparedness or cancer vaccine development, where rapid characterization of mutational impacts can inform both therapeutic design and immune surveillance strategies. Furthermore, synthetic DNA supports modular construct designs where epitope scaffolds, carrier proteins, and linkers can be rapidly interchanged, allowing researchers to test different antigen presentations and optimize for both immunogenicity and manufacturability. The ability to generate precise libraries of antigen variants also aids in mapping escape mutations in viral variants, such as in influenza, SARS-CoV-2, or HIV, helping researchers understand how pathogens evolve under immune pressure and design broader, more durable vaccines.
Another significant limitation of traditional cloning is the inadvertent inclusion of sequences that are toxic, unstable, or otherwise detrimental to the expression host. For example, bacterial expression of certain viral genes—especially those encoding regulatory proteins—can impair cell viability, reduce plasmid stability, or trigger stress responses that hinder protein production. Similarly, sequences with strong secondary structures, internal ribosome entry sites (IRES), or repetitive elements may cause DNA instability or interfere with transcription and translation.
Synthetic DNA offers the unique ability to redesign such sequences without altering the amino acid product. By introducing synonymous codon substitutions, cryptic splice sites, polyadenylation signals, or recombination hotspots can be removed. Secondary structures in mRNA can be disrupted to improve transcript stability and translational efficiency. Additionally, GC content and sequence repetitiveness can be balanced to minimize instability during plasmid replication or sequencing. These benefits are especially critical when designing vaccine antigens or therapeutic genes for viral vectors, where packaging capacity is limited and sequence integrity is paramount. For instance, synthetic DNA can exclude motifs that trigger innate immune sensors such as CpG islands in mammalian systems or reduce recombination risks in lentiviral or AAV vectors. Furthermore, for constructs requiring high biosafety containment or involving oncogenic sequences, synthetic DNA enables the safe recoding of functional domains to reduce pathogenicity while retaining immunological relevance. This allows early-stage research on challenging targets without compromising laboratory safety or regulatory compliance.
The ability to produce high yields of functional antigens is essential for vaccine development, diagnostics, and therapeutic protein production. However, researchers often encounter substantial obstacles when expressing recombinant proteins, particularly when the source organism differs from the host expression system. Traditional cloning methods—limited by native sequences, cloning site restrictions, and labor-intensive iteration—often fail to resolve low-yield or misfolding issues efficiently. In contrast, synthetic DNA enables a design-first approach, where codon optimization, regulatory elements, and sequence restructuring are engineered to maximize expression, solubility, and biological activity. This section highlights how DNA synthesis can drastically improve antigen yield, supported by a real-world comparison between bacterial and mammalian expression systems and the broader impact of sequence optimization on protein folding and function.
A common challenge in vaccine development is expressing viral proteins in lab-friendly systems. For example, researchers tried to produce a viral surface protein in E. coli using its original wild-type DNA sequence. However, they got very low expression, and most of the protein was misfolded or formed clumps called inclusion bodies. This happened because E. coli doesn't have the machinery to fold complex proteins or add sugars like mammalian cells do. The original gene also used codons that were rare in bacteria, which slowed translation and caused problems.
To solve this, the team used synthetic DNA to redesign the gene. They changed the codons to match E. coli preferences, removed problematic RNA structures, and added a bacterial secretion signal to send the protein to the periplasm, where folding is easier. These changes increased expression by 15 times and gave a soluble protein that could be purified more easily. Later, they made a version of the same antigen optimized for mammalian cells (like HEK293). Using synthetic DNA, they added a strong Kozak sequence, optimized codons for human cells, and included a mammalian secretion signal. This version was secreted into the culture medium and folded into the correct shape, including proper glycosylation. Tests showed that only the mammalian-expressed protein had the right structure to trigger neutralizing antibodies. This example shows that synthetic DNA not only improves protein yield but also gives scientists flexibility to choose the best expression system based on the final use of the antigen.
Antigen yield alone is not sufficient; the functional quality of the protein—its folding, structural integrity, and biological activity—is equally critical. Improperly folded proteins can lead to non-functional vaccines or diagnostic assays that fail to detect relevant antibodies. Synthetic DNA allows for comprehensive sequence optimization that promotes correct folding pathways and maintains antigenicity.
Key to this is managing translational kinetics through codon harmonization. Rapid translation can overwhelm cellular folding machinery, especially for multi-domain proteins or those requiring co-translational folding. Synthetic genes can be engineered to include "slow" codons at domain junctions or structurally sensitive regions, allowing ribosomes time to pause and enable proper folding. This technique has proven effective in producing viral capsid proteins and bacterial toxins with near-native structures. Protein activity can also be rescued or enhanced via synthetic design. In cases where the native antigen forms multimers or undergoes post-translational modifications, synthetic sequences can include artificial trimerization domains, protease cleavage sites, or engineered glycosylation motifs. These features not only promote correct quaternary structures but also enable site-specific purification, downstream processing, and vaccine formulation.
For example, in the development of a trimeric spike protein for a coronavirus vaccine, synthetic DNA enabled the introduction of two proline mutations and a furin cleavage site deletion—modifications known to stabilize the prefusion conformation of the spike. These changes dramatically improved the antigen's immunogenic profile, leading to stronger neutralizing antibody responses in animal models. Such rational antigen engineering would be extremely difficult without synthetic gene tools.
DNA synthesis services at BOC Sciences
Global Supplier of High-Quality RNA / DNA Products & Services.
